PMC5858648_01
(a) Clinical manifestation of mammary fibroadenomatous hyperplasia. (b) Cat after 1 week of treatment with aglepristone. (c) Complete remission of clinical signs after 4 weeks of treatment. (d) Follow-up after 3 months
10.1177_2055116918760155-fig1.jpg
PMC5858648_01_10.1177_2055116918760155-fig1.jpg
fig1-2055116918760155
Upon palpation, the axillary and abdominal breasts were warm and painful, and there was evidence of necrosis and ulceration of two of the mammary glands (Figure 1a). The histological examination showed widespread fibroadenomatous hyperplasia with proliferation of the ductal epithelium of the mammary glands, which confirmed the diagnosis of MFH (Figure 3 and Appendix 1 in the supplementary material). Six days after beginning the therapy, a reduction in size and change in the consistency of all mammary glands was already evident (Figure 1b). Complete remission of clinical signs was observed approximately 4 weeks later, similar to that reported in the literature (Figure 1c). Another follow-up was performed 3 months later, with no visible signs of disease recurrence observed (Figure 1d).
Ultrasonography of mammary glands with a homogeneous glandular structure and regular margins, characteristic of benign lesions
10.1177_2055116918760155-fig2.jpg
PMC5858648_01_10.1177_2055116918760155-fig2.jpg
fig2-2055116918760155
Histological image of fibroadenomatous hyperplasia. Stained with haematoxylin and eosin, x 10 magnification
10.1177_2055116918760155-fig3.jpg
PMC5858648_01_10.1177_2055116918760155-fig3.jpg
fig3-2055116918760155
The histological examination showed widespread fibroadenomatous hyperplasia with proliferation of the ductal epithelium of the mammary glands, which confirmed the diagnosis of MFH (Figure 3 and Appendix 1 in the supplementary material).